Unicycive Therapeutics Inc. (UNCY) has a regulatory catalyst to watch next month.
The company's lead drug candidate, oxylanthanum carbonate or OLC, is under FDA review for the treatment of hyperphosphatemia in chronic kidney disease or CKD patients on dialysis.
Hyperphosphatemia, characterized by elevated phosphate levels in the blood, is a common and serious condition in nearly all patients with End Stage Renal Disease (ESRD).
For comments and feedback contact: editorial@rttnews.com
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.